Your browser doesn't support javascript.
loading
T cell activation and IFNγ modulate organ dysfunction in LPS-mediated inflammation.
Taylor, Matthew D; Fernandes, Tiago D; Yaipen, Omar; Higgins, Cassidy E; Capone, Christine A; Leisman, Daniel E; Nedeljkovic-Kurepa, Ana; Abraham, Mabel N; Brewer, Mariana R; Deutschman, Clifford S.
Afiliación
  • Taylor MD; The Division of Critical Care Medicine, Department of Pediatrics, The Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Fernandes TD; Department of Pediatrics, Cohen Children's Medical Center/Northwell Health, New Hyde Park, New York, USA.
  • Yaipen O; The Division of Critical Care Medicine, Department of Pediatrics, The Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Higgins CE; Department of Pediatrics, Cohen Children's Medical Center/Northwell Health, New Hyde Park, New York, USA.
  • Capone CA; The Division of Critical Care Medicine, Department of Pediatrics, The Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Leisman DE; Department of Pediatrics, Cohen Children's Medical Center/Northwell Health, New Hyde Park, New York, USA.
  • Nedeljkovic-Kurepa A; The Division of Critical Care Medicine, Department of Pediatrics, The Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Abraham MN; Department of Pediatrics, Cohen Children's Medical Center/Northwell Health, New Hyde Park, New York, USA.
  • Brewer MR; The Division of Critical Care Medicine, Department of Pediatrics, The Feinstein Institutes for Medical Research, Manhasset, New York, USA.
  • Deutschman CS; Department of Pediatrics, Cohen Children's Medical Center/Northwell Health, New Hyde Park, New York, USA.
J Leukoc Biol ; 112(2): 221-232, 2022 08.
Article en En | MEDLINE | ID: mdl-35141943
LPS challenge is used to model inflammation-induced organ dysfunction. The effects of T cell activation on LPS-mediated organ dysfunction and immune responses are unknown. We studied these interactions through in vivo administration of anti-CD3ε (CD3) T cell activating antibody and LPS. Mortality in response to high-dose LPS (LPSHi; 600 µg) was 60%; similar mortality was observed with a 10-fold reduction in LPS dose (LPSLo; 60 µg) when administered with CD3 (CD3LPSLo). LPSHi and CD3LPSLo cohorts suffered severe organ dysfunction. CD3LPSLo led to increased IFNγ and IL12p70 produced by T cells and dendritic cells (cDCs) respectively. CD3LPSLo caused cDC expression of CD40 and MHCII and prevented PD1 expression in response to CD3. These interactions led to the generation of CD4 and CD8 cytolytic T cells. CD3LPSLo responded to IFNγ or IL12p40 blockade, in contrast to LPSHi. The combination of TCR activation and LPS (CD3LPSLo) dysregulated T cell activation and increased LPS-associated organ dysfunction and mortality through T cell and cDC interactions.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Activación de Linfocitos / Linfocitos T / Interferón gamma / Insuficiencia Multiorgánica Límite: Animals Idioma: En Revista: J Leukoc Biol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Activación de Linfocitos / Linfocitos T / Interferón gamma / Insuficiencia Multiorgánica Límite: Animals Idioma: En Revista: J Leukoc Biol Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos